Nakanishi K.,Asahikawa Kosei General Hospital |
Endo T.,Respiratory Center |
Endo T.,Asahikawa Kosei General Hospital |
Ohsaki Y.,Asahikawa University
Japanese Journal of Cancer and Chemotherapy | Year: 2017
A 62-year-old male was diagnosed with large cell lung cancer (c-Stage IV) based on pathological examination of an anterior chest tumor. He received chemotherapy with cisplatin, pemetrexed, and bevacizumab. He suffered from persistent hiccups from day 2 of the first course of chemotherapy. He was unsuccessfully treated with chlorpromazine, shakuyakukanzoto, and gabapentin. Therefore, we administered pregabalin to him, and his hiccups subsided immediately. To prevent hiccups, he subsequently took pregabalin along with his chemotherapy regimen, and was able to receive 4 courses of chemotherapy without persistent hiccups. Pregabalin is a possible therapeutic option for treating persistent chemotherapy-induced hiccups.
Choi W.S.,Korea University |
Kang C.-I.,Sungkyunkwan University |
Kim Y.,Center for Infectious Disease |
Choi J.-P.,Seoul Medical Center |
And 38 more authors.
Infection and Chemotherapy | Year: 2016
Background: From May to July 2015, the Republic of Korea experienced the largest outbreak of Middle East respiratory syndrome (MERS) outside the Arabian Peninsula. A total of 186 patients, including 36 deaths, had been diagnosed with MERS-coronavirus (MERS-CoV) infection as of September 30th, 2015. Materials and Methods: We obtained information of patients who were confirmed to have MERS-CoV infection. MERS-CoV infection was diagnosed using real-time reverse-transcriptase polymerase chain reaction assay. Results: The median age of the patients was 55 years (range, 16 to 86). A total of 55.4% of the patients had one or more coexisting medical conditions. The most common symptom was fever (95.2%). At admission, leukopenia (42.6%), thrombocytopenia (46.6%), and elevation of aspartate aminotransferase (42.7%) were observed. Pneumonia was detected in 68.3% of patients at admission and developed in 80.8% during the disease course. Antiviral agents were used for 74.7% of patients. Mechanical ventilation, extracorporeal membrane oxygenation, and convalescent serum were employed for 24.5%, 7.1%, and 3.8% of patients, respectively. Older age, presence of coexisting medical conditions including diabetes or chronic lung disease, presence of dyspnea, hypotension, and leukocytosis at admission, and the use of mechanical ventilation were revealed to be independent predictors of death. Conclusion: The clinical features of MERS-CoV infection in the Republic of Korea were similar to those of previous outbreaks in the Middle East. However, the overall mortality rate (20.4%) was lower than that in previous reports. Enhanced surveillance and active management of patients during the outbreak may have resulted in improved outcomes. © 2016 by The Korean Society of Infectious Diseases | Korean Society for Chemotherapy.
Imori Y.,Respiratory Center |
Fujimoto H.,Toranomon Hospital |
Hanada S.,Respiratory Center |
Uruga H.,Respiratory Center |
And 6 more authors.
Internal Medicine | Year: 2012
We herein report the case of an idiopathic aneurysm of the accessory hemiazygos vein diagnosed by contrast-enhanced computed tomography (CT) and angiography. The patient was asymptomatic, and a posterior mediastinal mass was incidentally found on CT. Because endoscopic ultrasonography showed no thrombus formation in the aneurysm, the patient was therefore managed conservatively. © 2012 The Japanese Society of Internal Medicine.
Takahashi Y.,Respiratory Center |
Uruga H.,Respiratory Center |
Fujii T.,Toranomon Hospital |
Fujii T.,Okinaka Memorial Institute for Medical Research |
And 8 more authors.
BMC Cancer | Year: 2016
Background: Pulmonary tumor thrombotic microangiopathy (PTTM), a rare complication of advanced cancer, is histologically characterized by tumor embolisms and fibrocellular intimal proliferation of small pulmonary arteries and arterioles. PTTM usually has an extremely poor prognosis, and antemortem diagnosis is very difficult. Case presentation: A 65-year-old woman with a 5-year history of clinical stage IIA (T2N0M0) invasive ductal carcinoma of the left breast was hospitalized for worsening shortness of breath, hemoptysis, and cough since 2 months. She had previously received neoadjuvant chemotherapy and left mastectomy. Because the cancer cells were positive for human epidermal growth factor receptor 2 (HER2), four cycles of trastuzumab had been administered as adjuvant chemotherapy. On admission, chest computed tomography (CT) showed peripheral consolidations in both the lower lobes and a mediastinal mass. Specimens obtained on video-assisted thoracoscopic surgical biopsy revealed tumor cell embolism, intimal fibrocellular proliferation of small arteries, fibrin thrombi, recanalization, and infarction in the left lower lobe, as well as metastasis to the mediastinal pleura. Immunohistochemical staining of the tumor cells revealed positivity for HER2, and a diagnosis of recurrent breast cancer with PTTM was made. Four cycles of trastuzumab resulted in rapid improvement of her symptoms and CT findings of peripheral consolidations and the mediastinal mass. Conclusion: An antemortem diagnosis of PTTM was made in a patient with HER2-positive recurrent breast cancer. Trastuzumab was effective for not only breast cancer but also PTTM. © 2016 The Author(s).
Yamamoto T.,Yokohama City University |
Oshima T.,Gastroenterological Center |
Yoshihara K.,Gastroenterological Center |
Yamanaka S.,Respiratory Center |
And 9 more authors.
Oncology Letters | Year: 2010
Claudin-7 is a tight junction protein that plays an important role in tumorigenesis, tumor invasion and metastasis. We examined the clinical significance of claudin-7 expression in 75 postsurgical non-small cell lung cancer (NSCLC) patients. Claudin-7 expression was measured immunohistochemically and was found to be high in 25 patients (33.3%) and low in 50 (66.7%). Survival was significantly poorer in patients with claudin-7-low than in those with claudin-7-high NSCLCs (P=0.024). In particular, survival was significantly poorer in patients with claudin-7-low than in those with claudin-7-high squamous cell carcinomas (P=0.011). A reduced expression of claudin-7 was associated with poor outcome in NSCLCs. Claudin-7 may thus be a useful biomarker and a potential therapeutic target in patients with NSCLC.
News Article | November 7, 2016
CLEVELAND, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Chart Industries, Inc. (Nasdaq:GTLS), a leading diversified global manufacturer of highly engineered equipment for the industrial gas, energy and biomedical industries, today announced an organizational realignment within its BioMedical Group to better position the company to capture future growth in the respiratory products industry. The Group will realign a portion of its manufacturing and engineering operations and establish a Respiratory Center-of-Excellence in Canton, GA where engineering, manufacturing, sales and marketing will be centralized to jointly develop and deliver industry leading respiratory products. To realize this change, the company expects to consolidate a majority of its U.S. respiratory operation and engineering activities into the existing Canton, GA campus, relocate key personnel, and suspend production and engineering of respiratory products at its Amherst, NY facility. “This transformation enables the company to improve collaboration and infrastructure utilization to drive product innovation, efficiency, speed, and quality,” said Earl Lawson, President of Chart BioMedical. “This realignment and our continued investment in respiratory solutions demonstrates our commitment to the industry and to improving the quality of life for millions of people suffering from COPD and other lung diseases. We are positioning the company to meet our strategic goal to have associated core engineering, manufacturing, sales and marketing resources located together to better support the growing demand for our products.” Chart is a leading diversified global manufacturer of highly engineered equipment for the industrial gas, energy, and biomedical industries. The majority of Chart's products are used throughout the liquid gas supply chain for purification, liquefaction, distribution, storage and end-use applications. Chart has domestic operations located across the United States and an international presence in Asia, Australia, Europe and South America. For more information, visit: http://www.chartindustries.com.
Koma Y.,Respiratory Center |
Inoue S.,Respiratory Center |
Oda N.,Respiratory Center |
Yokota N.,Respiratory Center |
And 9 more authors.
Clinical Respiratory Journal | Year: 2015
Background and Aims: Patients with pneumonia, a common cause of empyema, are stratified based on their risk factors, and the treatment of empyema might benefit from this risk stratification. Methods: The etiology, bacteriologic profile and outcome of patients diagnosed with empyema in Shinko Hospital between May 2005 and October 2013 were retrospectively studied. The patients were stratified according to whether they had community-acquired empyema (CAE), health-care-associated empyema (HCAE) or hospital-acquired empyema (HAE). Results: The study included 81 patients, 25 CAE, 40 HCAE and 16 HAE. The comorbidity rate was highest among HAE patients (100%), followed by 95% of HCAE and 72% of CAE patients (P=0.005). The rates of cancer and central nervous system (CNS) disease were higher in patients with HCAE and HAE than in patients with CAE (P=0.030, P=0.018, respectively). Pleural fluid cultures were positive in 58/81 patients. Streptococcus species were the most common organisms cultured from CAE (12/15) and HCAE patients (17/30), but not from HAE patients (3/13). Anaerobic organisms were cultured from 3 CAE, 5 HCAE and 3 HAE patients. Methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa were only cultured from HCAE and HAE patients. The mortality rates were higher in HCAE (18%) and HAE (50%) than in CAE (4%) patients (log-rank test: P=0.0012). Conclusions: Half of patients with empyema were HCAE patients, who had comorbidities, bacteriological profile and outcome different from CAE patients. The patient with HCAE should be differentiated from CAE patient, and the stratification of patients based on risk factors may be useful for treatment strategy. © 2015 John Wiley & Sons Ltd.
PubMed | Respiratory Center
Type: Case Reports | Journal: Internal medicine (Tokyo, Japan) | Year: 2012
We herein report the case of an idiopathic aneurysm of the accessory hemiazygos vein diagnosed by contrast-enhanced computed tomography (CT) and angiography. The patient was asymptomatic, and a posterior mediastinal mass was incidentally found on CT. Because endoscopic ultrasonography showed no thrombus formation in the aneurysm, the patient was therefore managed conservatively.